Anavex Life Sciences Corp. (AVXL)

Market Cap	718.64M
Revenue (ttm)	n/a
Net Income (ttm)	-41.53M
Shares Out	84.80M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	909,493
Open	8.28
Previous Close	8.24
Day's Range	8.05 - 8.48
52-Week Range	3.25 - 10.45
Beta	0.60
Analysts	Strong Buy
Price Target	43.00 (+407.38%)
Earnings Date	Dec 3, 2024

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company’s drug candidate also comprises ANAVEX 3-71, which ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: AVXL
• Website: https://www.anavex.com

Analyst Forecast

According to 2 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is $43.0, which is an increase of 407.38% from the latest price.

Price Target

$43.0

(407.38% upside)

Analyst Consensus: Strong Buy